These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 33450205)

  • 1. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.
    Bowling EA; Wang JH; Gong F; Wu W; Neill NJ; Kim IS; Tyagi S; Orellana M; Kurley SJ; Dominguez-Vidaña R; Chung HC; Hsu TY; Dubrulle J; Saltzman AB; Li H; Meena JK; Canlas GM; Chamakuri S; Singh S; Simon LM; Olson CM; Dobrolecki LE; Lewis MT; Zhang B; Golding I; Rosen JM; Young DW; Malovannaya A; Stossi F; Miles G; Ellis MJ; Yu L; Buonamici S; Lin CY; Karlin KL; Zhang XH; Westbrook TF
    Cell; 2021 Jan; 184(2):384-403.e21. PubMed ID: 33450205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
    Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
    Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spliceosome-Targeted Therapies Induce dsRNA Responses.
    Ishak CA; Loo Yau H; De Carvalho DD
    Immunity; 2021 Jan; 54(1):11-13. PubMed ID: 33440135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging roles of spliceosome in cancer and immunity.
    Yang H; Beutler B; Zhang D
    Protein Cell; 2022 Aug; 13(8):559-579. PubMed ID: 34196950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay between A-to-I Editing and Splicing of RNA: A Potential Point of Application for Cancer Therapy.
    Goncharov AO; Shender VO; Kuznetsova KG; Kliuchnikova AA; Moshkovskii SA
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA splicing, cell signaling, and response to therapies.
    Abou Faycal C; Gazzeri S; Eymin B
    Curr Opin Oncol; 2016 Jan; 28(1):58-64. PubMed ID: 26575690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
    Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
    Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
    Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer.
    Cieśla M; Ngoc PCT; Cordero E; Martinez ÁS; Morsing M; Muthukumar S; Beneventi G; Madej M; Munita R; Jönsson T; Lövgren K; Ebbesson A; Nodin B; Hedenfalk I; Jirström K; Vallon-Christersson J; Honeth G; Staaf J; Incarnato D; Pietras K; Bosch A; Bellodi C
    Mol Cell; 2021 Apr; 81(7):1453-1468.e12. PubMed ID: 33662273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
    Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency.
    Mehdipour P; Marhon SA; Ettayebi I; Chakravarthy A; Hosseini A; Wang Y; de Castro FA; Loo Yau H; Ishak C; Abelson S; O'Brien CA; De Carvalho DD
    Nature; 2020 Dec; 588(7836):169-173. PubMed ID: 33087935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate metabolism negatively regulates OAS-mediated antiviral innate immunity via ADAR3/endogenous dsRNA pathway.
    Wu J; You Q; Lyu R; Qian Y; Tao H; Zhang F; Cai Y; Jiang N; Zheng N; Chen D; Wu Z
    Metabolism; 2023 Jun; 143():155526. PubMed ID: 36822494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition effect of exosomes-mediated Let-7a on the development and metastasis of triple negative breast cancer by down-regulating the expression of c-Myc.
    Du J; Fan JJ; Dong C; Li HT; Ma BL
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5301-5314. PubMed ID: 31298382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of triple-negative breast cancers based on Immunogenomic profiling.
    He Y; Jiang Z; Chen C; Wang X
    J Exp Clin Cancer Res; 2018 Dec; 37(1):327. PubMed ID: 30594216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Minor Splicing Patterns across Cancers.
    Levesque L; Salazar N; Roy SW
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.
    Suda K; Rozeboom L; Yu H; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    PLoS One; 2017; 12(2):e0172209. PubMed ID: 28192473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splicing segregation: the minor spliceosome acts outside the nucleus and controls cell proliferation.
    König H; Matter N; Bader R; Thiele W; Müller F
    Cell; 2007 Nov; 131(4):718-29. PubMed ID: 18022366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of antiviral innate immunity by birnavirus VP3 protein via blockage of viral double-stranded RNA binding to the host cytoplasmic RNA detector MDA5.
    Ye C; Jia L; Sun Y; Hu B; Wang L; Lu X; Zhou J
    J Virol; 2014 Oct; 88(19):11154-65. PubMed ID: 25031338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.